Amitriptyline/Ketamine

阿米替林/氯胺酮

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAmitriptyline/Ketamine
Drug Alias NameKetamine/amitriptyline氯胺酮阿米替林Ketamine+amitriptyline阿米替林氯胺酮氯胺酮/阿米替林 +[10] 
ClassificationSmall molecules
Mechanisms of ActionMonoamine reuptake inhibitorGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptorMonoamine transporters
Therapy Area/IndicationsDiabetic peripheral neuropathySolid tumoursPain +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIndia
CombinationsYes Amitriptyline hydrochlorideKetamine Hydrochloride
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmune Pharmaceuticals IncNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesImmune Pharmaceuticals IncNational Cancer Institute
Inactive CompaniesEpicept Co
Active IndicationsPainNeurotoxicity SyndromesPeripheral Nervous System Diseases
Inactive IndicationsDiabetic peripheral neuropathySolid tumoursNeuralgia, Postherpetic +[5] 

Other Information

ATC CodeN/A
Related LinksN/A